Guidelines recommend the breast cancer risk reducing medications (RRMs) tamoxifen, raloxifene, and aromatase inhibitors (AIs) for women at increased breast cancer risk.
However, use of RRMs in this population is low.
We assessed RRM trends in older women enrolled in a cancer screening trial.
